Search by Drug Name or NDC
NDC 64406-0019-01 Byooviz 10 mg/mL Details
Byooviz 10 mg/mL
Byooviz is a INTRAVITREAL INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by BIOGEN INC.. The primary component is RANIBIZUMAB.
MedlinePlus Drug Summary
Ranibizumab injection products are used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Ranibizumab implant (Susvimo) is also used to treat wet age-related macular degeneration after at least two successful treatments with ranibizumab or a similar medication. Ranibizumab injection products are also used to treat myopic choroidal neovascularization (mCNV; a complication in near-sighted people where new blood vessels can grow in the back of the eye) and to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss). Ranibizumab injection (Lucentis) is also used to treat diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes). Ranibizumab is in a class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss.
Related Packages: 64406-0019-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Ranibizumab Injection
Product Information
| NDC | 64406-0019 |
|---|---|
| Product ID | 64406-019_bc93c0a1-2d15-47c6-aadb-29244dfcc202 |
| Associated GPIs | 86655060502020 |
| GCN Sequence Number | 082681 |
| GCN Sequence Number Description | ranibizumab-nuna VIAL 0.5MG/0.05 INTRAOCULR |
| HIC3 | Q2F |
| HIC3 Description | OPHTH. VEGF-A RECEPTOR ANTAG. RCMB MC ANTIBODY |
| GCN | 51027 |
| HICL Sequence Number | 047583 |
| HICL Sequence Number Description | RANIBIZUMAB-NUNA |
| Brand/Generic | Brand |
| Proprietary Name | Byooviz |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ranibizumab-nuna |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVITREAL |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | RANIBIZUMAB |
| Labeler Name | BIOGEN INC. |
| Pharmaceutical Class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761202 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 64406-0019-01 (64406001901)
| NDC Package Code | 64406-019-01 |
|---|---|
| Billing NDC | 64406001901 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (64406-019-01) / .05 mL in 1 VIAL, SINGLE-DOSE (64406-019-07) |
| Marketing Start Date | 2022-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |